Updates are available Correction dated 2024-08-28
Click to view Correction: https://doi.org/10.1038/s41591-024-03260-8
-
Authors
Choueiri, Toni K. https://orcid.org/0000-0002-9201-3217
Kaelin, William G. Jr
- License Information
-
More Information
Article History
Received: 11 April 2020
Accepted: 2 September 2020
First Online: 5 October 2020
Change Date: 28 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03260-8
Competing interests
: T.K.C. reports receiving research support (institutional and personal) from AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb/ER Squibb & Sons, Cerulean, Eisai, Foundation Medicine, Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, and Takeda; honoraria from AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers Squibb/ER Squibb & Sons, Cerulean, Eisai, Foundation Medicine, Exelixis, Genentech, Roche, Roche Products, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, Analysis Group, National Comprehensive Cancer Network, Michael J. Hennessy (MJH) Associates (healthcare communications company with several brands, such as OncLive, PeerView and PER), Research to Practice, L-path, <i>Kidney Cancer</i> journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, <i>New England Journal of Medicine</i>, <i>Lancet Oncology</i>, Heron Therapeutics and Lilly; has had a consulting or advisory role for AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers Squibb/ER Squibb & Sons, Cerulean, Eisai, Foundation Medicine, Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, National Comprehensive Cancer Network, Analysis Group, Pionyr and Tempest; owns stock in Pionyr and Tempest; and has received travel, accommodations, and expenses in relation to consulting, advisory roles or honoraria. W.G.K. is a board director at Lilly Pharmaceuticals, is a founder of Tango Therapeutics and Cedilla Therapeutics, is a Scientific Advisor at Nextech Invest, has ownership interest (including stock, patents, etc.) in Lilly, Tango Therapeutics, Nextech Invest and Cedilla Therapeutics, and is a consultant/advisory board member for Lilly Pharmaceuticals, Tango Therapeutics, Nextech Invest and Cedilla Therapeutics.
